NCT00899470 - Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Co-administration of Saxagliptin and Metformin IR, Fasted

Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions

DRUG

Saxagliptin/Metformin, Fasting

Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions

DRUG

Co-administration of Saxagliptin and Metformin IR, Fed

Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions

DRUG

Saxagliptin/Metformin, Fed

Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions

Trial Locations (1)

68502

Mds Pharma Services, Lincoln